文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

胰高血糖素样肽-1受体激动剂与二肽基肽酶-4抑制剂使用与2型糖尿病合并晚期慢性肾脏病患者死亡率的关联

Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
PubMed 文献 · JAMA Netw Open · 2022-03-01
一句话结论在2型糖尿病合并晚期CKD或ESKD患者中,回顾性队列显示GLP-1受体激动剂较DPP-4抑制剂与更低的全因死亡率和脓毒症/感染相关死亡率相关。

本研究为回顾性队列研究,利用台湾全民健康保险研究数据库2012年1月1日至2018年12月31日的数据,纳入27 279例2型糖尿病合并5期CKD或ESKD患者,比较GLP-1受体激动剂(701例)与DPP-4抑制剂(26 578例)使用者的结局。经倾向评分加权后,GLP-1受体激动剂组全因死亡率更低(HR 0.79;95%CI 0.63-0.98),脓毒症和感染相关死亡率更低(HR 0.61;95%CI 0.40-0.91)。亚组分析显示,合并脑血管病患者中GLP-1受体激动剂与更低死亡风险相关(HR 0.33;95%CI 0.12-0.86),无脑血管病患者中HR 0.89(95%CI 0.71-1.12),交互作用P=0.04。作者认为需要额外精心设计的前瞻性研究来证实GLP-1受体激动剂对晚期CKD或ESKD患者的潜在获益。

要点

  • 在2型糖尿病合并5期CKD或ESKD患者中,倾向评分加权后GLP-1受体激动剂组全因死亡率低于DPP-4抑制剂组(HR 0.79;95%CI 0.63-0.98)。
  • GLP-1受体激动剂组脓毒症和感染相关死亡率低于DPP-4抑制剂组(HR 0.61;95%CI 0.40-0.91)。
  • 合并脑血管病患者中GLP-1受体激动剂与更低死亡风险相关(HR 0.33;95%CI 0.12-0.86),无脑血管病患者HR 0.89(95%CI 0.71-1.12),交互作用P=0.04。
  • 该研究为回顾性队列,作者认为需额外精心设计的前瞻性研究证实GLP-1受体激动剂在晚期CKD或ESKD患者中的潜在获益。

适用人群与场景

  • 纳入:2型糖尿病合并5期慢性肾脏病(CKD)或终末期肾病(ESKD)患者,数据来自台湾全民健康保险研究数据库,研究期间为2012年1月1日至2018年12月31日。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量:27 279例;数据来源:台湾全民健康保险研究数据库;研究期间:2012年1月1日至2018年12月31日;数据分析时间:2020年6月至2021年7月。
  • 人群:DPP-4抑制剂组26 578例(男性14 443例[54.34%];平均[SD]年龄65[13]岁);GLP-1受体激动剂组701例(男性346例[49.36%];平均[SD]年龄59[13]岁)。
  • 干预与对照:GLP-1受体激动剂治疗对比DPP-4抑制剂治疗;采用倾向评分加权平衡组间协变量。
  • 主要终点:全因死亡率,GLP-1受体激动剂组低于DPP-4抑制剂组(HR 0.79;95%CI 0.63-0.98);脓毒症和感染相关死亡率,GLP-1受体激动剂组低于DPP-4抑制剂组(HR 0.61;95%CI 0.40-0.91)。
  • 亚组分析:合并脑血管病患者中GLP-1受体激动剂组死亡风险低于DPP-4抑制剂组(HR 0.33;95%CI 0.12-0.86);无脑血管病患者中HR 0.89(95%CI 0.71-1.12);交互作用P=0.04。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性;作者在结论中指出需要额外精心设计的前瞻性研究来证实GLP-1受体激动剂对晚期CKD或ESKD患者的潜在获益。

对床旁实践的改变

  • 作者认为,在2型糖尿病合并晚期CKD或ESKD患者中,GLP-1受体激动剂治疗与较低的全因死亡率相关,但需要额外精心设计的前瞻性研究来证实其潜在获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Glucagon-like peptide-1 (GLP-1) receptor agonist use is associated with reduced mortality and improved cardiovascular outcomes in the general population with diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used antidiabetic agents for patients with advanced-stage chronic kidney disease (CKD). The association of these 2 drug classes with outcomes among patients with diabetes and advanced-stage CKD or end-stage kidney disease (ESKD) is not well understood.

OBJECTIVE: To assess whether use of GLP-1 receptor agonists in a population with diabetes and advanced-stage CKD or ESKD is associated with better outcomes compared with use of DPP-4 inhibitors.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data on patients with type 2 diabetes and stage 5 CKD or ESKD obtained from the National Health Insurance Research Database of Taiwan. The study was conducted between January 1, 2012, and December 31, 2018. Data were analyzed from June 2020 to July 2021.

EXPOSURES: Treatment with GLP-1 receptor agonists compared with treatment with DPP-4 inhibitors.

MAIN OUTCOMES AND MEASURES: All-cause mortality, sepsis- and infection-related mortality, and mortality related to major adverse cardiovascular and cerebrovascular events were compared between patients treated with GLP-1 receptor agonists and patients treated with DPP-4 inhibitors. Propensity score weighting was used to mitigate the imbalance among covariates between the groups.

RESULTS: Of 27 279 patients included in the study, 26 578 were in the DPP-4 inhibitor group (14 443 [54.34%] male; mean [SD] age, 65 [13] years) and 701 in the GLP-1 receptor agonist group (346 [49.36%] male; mean [SD] age, 59 [13] years). After weighting, the use of GLP-1 receptor agonists was associated with lower all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.63-0.98) and lower sepsis- and infection-related mortality (HR, 0.61; 95% CI, 0.40-0.91). Subgroup analysis demonstrated a lower risk of mortality associated with use of GLP-1 receptor agonists compared with DDP-4 inhibitors among patients with cerebrovascular disease (HR, 0.33; 95% CI, 0.12-0.86) than among those without cerebrovascular disease (HR, 0.89; 95% CI, 0.71-1.12) (P = .04 for interaction).

CONCLUSIONS AND RELEVANCE: Treatment with GLP-1 receptor agonists was associated with lower all-cause mortality among patients with type 2 diabetes, advanced-stage CKD, and ESKD than was treatment with DPP-4 inhibitors. Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chen JJ, Wu CY, Jenq CC, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. JAMA Netw Open. 2022. PMID: 35254430. doi:10.1001/jamanetworkopen.2022.1169

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。